Literature DB >> 12447359

Serum-derived protein S binds to phosphatidylserine and stimulates the phagocytosis of apoptotic cells.

Howard A Anderson1, Caroline A Maylock, Joy A Williams, Cloud P Paweletz, Hongjun Shu, Emily Shacter.   

Abstract

Rapid phagocytosis of apoptotic cells is thought to limit the development of inflammation and autoimmune disease. Serum enhances macrophage phagocytosis of apoptotic cells. Here we identified protein S as the factor responsible for serum-stimulated phagocytosis of apoptotic cells. Protein S is best known for its anti-thrombotic activity, serving as a cofactor for protein C. Purified protein S was equivalent to serum in its ability to stimulate macrophage phagocytosis of apoptotic lymphoma cells, and immunodepletion of protein S eliminated the prophagocytic activity of serum. Protein S acted by binding to phosphatidylserine expressed on the apoptotic cell surface. Protein S is thus a multifunctional protein that can facilitate clearance of early apoptotic cells in addition to regulating blood coagulation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12447359     DOI: 10.1038/ni871

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  121 in total

Review 1.  Phagocytosis of opsonized apoptotic cells: roles for 'old-fashioned' receptors for antibody and complement.

Authors:  S P Hart; J R Smith; I Dransfield
Journal:  Clin Exp Immunol       Date:  2004-02       Impact factor: 4.330

Review 2.  The retinal pigment epithelium in health and disease.

Authors:  J R Sparrow; D Hicks; C P Hamel
Journal:  Curr Mol Med       Date:  2010-12       Impact factor: 2.222

3.  Identification of novel binding partners (annexins) for the cell death signal phosphatidylserine and definition of their recognition motif.

Authors:  Sabrina Rosenbaum; Sandra Kreft; Julia Etich; Christian Frie; Jacek Stermann; Ivan Grskovic; Benjamin Frey; Dirk Mielenz; Ernst Pöschl; Udo Gaipl; Mats Paulsson; Bent Brachvogel
Journal:  J Biol Chem       Date:  2010-12-03       Impact factor: 5.157

4.  Human CD300a binds to phosphatidylethanolamine and phosphatidylserine, and modulates the phagocytosis of dead cells.

Authors:  Venkateswara R Simhadri; John F Andersen; Eric Calvo; Seung-Chul Choi; John E Coligan; Francisco Borrego
Journal:  Blood       Date:  2012-02-01       Impact factor: 22.113

5.  High molecular weight kininogen binds phosphatidylserine and opsonizes urokinase plasminogen activator receptor-mediated efferocytosis.

Authors:  Aizhen Yang; Jihong Dai; Zhanli Xie; Robert W Colman; Qingyu Wu; Raymond B Birge; Yi Wu
Journal:  J Immunol       Date:  2014-03-31       Impact factor: 5.422

6.  The positive inotropic agent DPI-201106 selectively reverses ABCB1-mediated multidrug resistance in cancer cell lines.

Authors:  Sung-Han Hsiao; Megumi Murakami; Ni Yeh; Yan-Qing Li; Tai-Ho Hung; Yu-Shan Wu; Suresh V Ambudkar; Chung-Pu Wu
Journal:  Cancer Lett       Date:  2018-07-18       Impact factor: 8.679

7.  Opposing Roles of Tyrosine Kinase Receptors Mer and Axl Determine Clinical Outcomes in Experimental Immune-Mediated Nephritis.

Authors:  Yuxuan Zhen; Stephen O Priest; Wen-Hai Shao
Journal:  J Immunol       Date:  2016-08-15       Impact factor: 5.422

Review 8.  TAM receptor deficiency affects adult hippocampal neurogenesis.

Authors:  Rui Ji; Lingbin Meng; Qiutang Li; Qingxian Lu
Journal:  Metab Brain Dis       Date:  2014-12-10       Impact factor: 3.584

9.  Genetic dissection of TAM receptor-ligand interaction in retinal pigment epithelial cell phagocytosis.

Authors:  Tal Burstyn-Cohen; Erin D Lew; Paqui G Través; Patrick G Burrola; Joseph C Hash; Greg Lemke
Journal:  Neuron       Date:  2012-12-20       Impact factor: 17.173

10.  Brazilian marine sponge Polymastia janeirensis induces apoptotic cell death in human U138MG glioma cell line, but not in a normal cell culture.

Authors:  Mario Luiz Conte da Frota; Elizandra Braganhol; Andrés Delgado Canedo; Fabio Klamt; Miriam Anders Apel; Beatriz Mothes; Cléa Lerner; Ana Maria Oliveira Battastini; Amélia Teresinha Henriques; José Cláudio Fonseca Moreira
Journal:  Invest New Drugs       Date:  2008-05-03       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.